FDA Approves TECNIS PureSee IOL for Cataract Surgery
First FDA-approved extended depth of focus (EDOF) IOL maintaining contrast sensitivity comparable to an aspheric monofocal IOL
Clinical Scorecard: FDA Approves TECNIS PureSee IOL for Cataract Surgery
At a Glance
| Category | Detail |
|---|
| Condition | Cataracts and presbyopia |
| Key Mechanisms | Extended depth of focus (EDOF) intraocular lens (IOL) that addresses cataract-related vision loss and presbyopia effects. |
| Target Population | Patients aged 50 and over with moderate-to-severe distance vision impairment or blindness. |
| Care Setting | Cataract surgery |
Key Highlights
- First FDA-approved EDOF IOL with no warning on loss of contrast sensitivity.
- Maintains contrast sensitivity comparable to aspheric monofocal IOLs.
- 97% of patients report no very bothersome visual disturbances post-surgery.
- Provides excellent distance and intermediate vision, with some near vision.
- Reduces reliance on glasses following surgery.
Guideline-Based Recommendations
Diagnosis
- Assess cataract severity and impact on vision.
Management
- Consider TECNIS PureSee IOL for patients undergoing cataract surgery.
Monitoring & Follow-up
- Evaluate visual outcomes and patient satisfaction post-surgery.
Risks
- Monitor for potential visual disturbances, although low incidence reported.
Patient & Prescribing Data
Patients aged 50 and over with cataracts and presbyopia.
TECNIS PureSee IOL offers a solution for both cataract correction and presbyopia management.
Clinical Best Practices
- Ensure thorough pre-operative assessment of visual needs.
- Discuss potential outcomes and benefits of TECNIS PureSee IOL with patients.
- Follow up with patients to monitor visual clarity and satisfaction.
Related Resources & Content
